CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue ...

What did the recent study using the crispr gene editing technique actually entail, and what did we learn from it? Hosted by: Hank Green Dooblydoo thanks go to the following Patreon supporters: Kevin ...

March 27 (Reuters) - A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for a second time in their dispute with the Broad ...

In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally evolved gene-editing system that can activate genes, offering an advantage ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

Biotechnology startup CRISPR Therapeutics is issuing debt to continue developing its drug portfolio and pipeline. This new debt and/or the shareholder dilution it may lead to, however, will likely be ...

(via SciShow) From the non-bubonic plague that killed a Welsh king, to the deadliest pestilence in 16th century Mexico, to a pandemic we're currently in the middle of (No, it's not coronavirus), here ...

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme elevations in one patient, who died a few days later. Intellia Therapeutics can now ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death. The agency has ...